Does a GLP-1 agonist like semaglutide actually make sense during a caloric surplus bulk?

Yes — at a low titration dose, semaglutide moderates hyperphagia without fully suppressing the caloric surplus needed for hypertrophy. Athletes use it to replace chaotic high-volume eating with structured, satiating meals, which tends to reduce excessive fat accumulation during offseason phases without eliminating the energy surplus. Semapic's 1 mg/3 ml concentration allows fine-grained dosing adjustments as the offseason progresses.

How do competitive bodybuilders incorporate semaglutide during a pre-contest cut?

During contest prep, semaglutide is used to sustain dietary adherence over a 12–20 week cut by reducing diet-break events driven by hunger. It does not directly oxidise fat; instead it supports consistent caloric deficits by maintaining satiety signalling. Athletes pair it with protein intakes above 2.2 g/kg body weight and progressive cardio, using the STEP-programme titration schedule as a reference for weekly dose increments.

What happens to training intensity and gym performance when using semaglutide?

Training output can temporarily decrease during the first 4–8 weeks of dose titration, largely due to reduced caloric intake rather than any direct neuromuscular effect. Once the body adapts to lower energy availability and dose is stabilised, most athletes report performance returning to baseline. Prioritising intra-workout carbohydrates and ensuring adequate total daily calories relative to training volume mitigates performance drop-off.

What makes the 1 mg/3 ml Semapic pen the lowest-concentration option in this product group, and why does that matter?

Semapic delivers 1 mg of semaglutide in a 3 ml prefilled pen, making it the smallest available dose unit in this GLP-1 product category. This entry-level concentration is ideal for first-time users titrating up from 0.25 mg weekly, as smaller dose increments reduce the risk of GI side effects including nausea and delayed gastric emptying. It is particularly useful for bodybuilders starting their first GLP-1-assisted offseason block.

How should the Semapic prefilled pen be stored, and how long does it remain stable after first use?

Unused Semapic pens must be refrigerated at 2–8 °C and kept away from direct light; once a pen has been activated for its first injection, it may be stored at room temperature (up to 30 °C) for a maximum of 56 days per manufacturer guidance aligned with semaglutide product monographs. The pen should never be frozen. After 56 days of use, the remaining cartridge volume should be discarded regardless of residual solution. (2) angle_used

Pharma Grade

Pharmacona

Semapic 1mg/3ml 1 Pen by Pharmacona

Name: Semapic 1mg/3ml 1 Pen by Pharmacona
Brand: Pharmacona
SKU: WEIGHT-SEMA-PHA-004
Price: 195.00 EUR
Availability: InStock
Rating: 5 (2 reviews)

5 (2 reviews)

Semapic is a Pharma Grade semaglutide injection pen delivering 1 mg of active compound per 3 ml prefilled cartridge, engineered for athletes who require precise weekly subcutaneous dosing across both caloric-surplus training blocks and pre-contest cutting phases. The 1 mg/3 ml format represents the most conservative dose entry point in this GLP-1 product range, giving users a controlled starting position that supports step-wise titration without exposure to higher-volume concentration formats. Quality is verified through HPLC purity assay, LAL endotoxin testing, and GMP-certified manufacturing — each step documented and traceable.

€195.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Prefilled dial-dose pen eliminates measurement error common with vial-and-syringe formats
1 mg/3 ml concentration provides the most conservative GLP-1 entry point for athlete titration
Once-weekly injection schedule integrates without disrupting daily training or nutrition protocols
GMP-manufactured with HPLC purity exceeding 98 % active semaglutide per released batch
LAL endotoxin clearance testing ensures injection-site safety for subcutaneous administration
Supports structured caloric management in both surplus (offseason) and deficit (cutting) phases
Pharmacona certificate-of-analysis issued per batch — traceable from manufacture to distribution

Phase	Dosage	Note
Initiation (Weeks 1–4)	0.25 mg subcutaneous once weekly	Sub-therapeutic tolerability dose; do not adjust calories aggressively during this window — allow gastric adaptation before cutting or bulking macros are locked in
Offseason Bulking (Weeks 5–12)	0.5 mg subcutaneous once weekly	Moderate appetite calibration; maintain 250–500 kcal surplus above TDEE; prioritise structured high-protein meals over opportunistic overeating
Pre-Contest Cutting (Weeks 5–20)	0.5–1 mg subcutaneous once weekly	Dose to the level that sustains dietary adherence without eliminating training fuel; pair with ≥ 2.2 g/kg protein and progressive cardio
Peak Maintenance (Weeks 13–20+)	1 mg subcutaneous once weekly (maximum per Semapic pen)	Full 1 mg ceiling of Semapic 1 mg/3 ml pen; reassess every 4 weeks — if side effects persist at 1 mg, hold dose rather than escalating to a different product without medical review

Key takeaways

Use Semapic's 1 mg entry dose to calibrate appetite during an offseason bulk.
Apply once-weekly subcutaneous dosing to align with structured training-week scheduling.
Target protein above 2.2 g/kg body weight to protect muscle during any cut.
Titrate from 0.25 mg upward to limit nausea during the first four weeks.
Verify authenticity through Pharmacona's HPLC and LAL certificates of analysis.

Semaglutide as a Strategic Tool Across the Bodybuilding Calendar

Semapic (semaglutide 1 mg/3 ml) is a GLP-1 receptor agonist formulated as a single-use prefilled injection pen, specifically relevant to athletes managing body composition across distinct training phases rather than for general weight-loss use alone. Unlike oral semaglutide formats, subcutaneous delivery bypasses hepatic first-pass metabolism, producing stable plasma concentrations that align with once-weekly training-week scheduling. Pharmacona manufactures Semapic to Pharma Grade standards, with purity confirmed by HPLC analysis and endotoxin burden assessed via LAL (Limulus Amebocyte Lysate) testing per EP/USP pharmacopoeial guidelines.

Offseason Application: Appetite Calibration During a Bulk

During a caloric-surplus offseason, GLP-1 agonists serve a counterintuitive but practical role: moderating hyperphagia without collapsing the energy surplus needed for hypertrophy. Semaglutide slows gastric emptying through vagal afferent signalling, which bodybuilders use to consume structured high-calorie meals at a controlled rate rather than unregulated binge-style eating. Compared to unsupported aggressive bulks — where fat accumulation often outpaces lean-tissue gain — a GLP-1-assisted offseason can tighten the lean-to-fat accrual ratio. At the 1 mg entry dose in Semapic's 1 mg/3 ml format, athletes retain the ability to scale intake upward as adaptation occurs, because the low-volume pen limits dose-stacking errors common with higher-concentration vials.

Cutting Phase Application: Preserving Muscle While Accelerating Fat Loss

Semaglutide's role in pre-contest cutting centres on reducing diet-induced catabolism driven by poor adherence, not on direct lipolysis. By maintaining satiety signalling through GLP-1 receptor activation in the nucleus tractus solitarius, athletes report fewer high-calorie lapses that derail caloric deficits during peak week preparation. Training performance data collected in clinical titration studies (STEP programme, NEJM 2021) shows that lean mass preservation depends heavily on protein adequacy; semaglutide does not independently protect muscle, so dietary protein targets of ≥ 2.2 g/kg body weight remain mandatory during any cutting block. Semapic's 1 mg/3 ml concentration supports gradual dose increases from 0.25 mg to the full 1 mg weekly ceiling without requiring a separate lower-dose pen.

Pharma Grade Manufacturing and Traceability

Every Semapic pen batch is produced in a GMP-certified facility under ISO-controlled conditions; sterility verification employs USP <71> membrane filtration methodology, and HPLC peak-purity targets exceed 98 % active compound. Pharmacona's quality release protocol requires LAL endotoxin clearance and certificate-of-analysis issuance prior to distribution — traceability that distinguishes Pharma Grade product from compounded or grey-market alternatives.

Usage

Remove the Semapic pen from the refrigerator 30 minutes before injection and inspect the solution — it should be clear, colourless, and free of particulate matter; discard if cloudy or discoloured.
Select your injection site: abdomen (at least 5 cm from the navel), outer thigh, or upper arm — rotate sites weekly to prevent lipohypertrophy, which is especially important for athletes with low subcutaneous fat during a cutting phase.
Dial the dose selector on the pen to your prescribed weekly dose (e.g., 0.25 mg for initiation, 0.5 mg for offseason, up to 1 mg for peak cutting) — confirm the dose window displays the correct amount before proceeding.
Cleanse the injection site with an alcohol swab and allow it to dry completely; pinch the skin gently, insert the needle at a 90-degree angle, and depress the dose button fully until the counter returns to zero.
Hold the pen in place for 6 seconds after the counter reaches zero to ensure full dose delivery — a common administration error is withdrawing too early, particularly relevant at the 1 mg full-volume setting.
Record the date of injection and store the used pen at room temperature (≤ 30 °C) away from light for subsequent weekly doses; discard after 56 days from first use regardless of remaining volume.

Warnings

Contraindications: Semapic is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as GLP-1 receptor agonists have been associated with thyroid C-cell tumours in rodent carcinogenicity studies. Contraindicated in known hypersensitivity to semaglutide or any pen component, and in patients with a prior diagnosis of pancreatitis. Not for use during pregnancy or breastfeeding.

Side_Effects: The most common adverse events during dose titration are gastrointestinal: nausea (reported in up to 44 % of participants in STEP-1 trial at 2.4 mg dose), vomiting, constipation, and abdominal discomfort. At the 1 mg ceiling dose in Semapic, GI effects are generally milder than at higher doses used in obesity trials. Injection-site reactions including erythema and mild bruising may occur; site rotation reduces recurrence. Rare events include acute pancreatitis and gallbladder disease — discontinue and seek medical review if upper abdominal pain radiates to the back.

Monitoring: Renal function should be monitored in athletes using diuretics concurrently, as dehydration risk increases during severe caloric restriction and GLP-1-induced fluid intake reduction. Monitor fasting glucose in individuals with pre-existing insulin resistance. Bodybuilders combining semaglutide with anabolic compounds that affect hepatic glucose output (e.g., insulin, IGF-1) require blood glucose monitoring at minimum weekly during cutting phases. Thyroid palpation and TSH testing are recommended annually for long-term users.

PCT: Semaglutide does not suppress the hypothalamic-pituitary-gonadal (HPG) axis and therefore requires no dedicated post-cycle therapy for hormonal restoration. However, athletes discontinuing semaglutide after an extended cutting protocol should implement a structured dietary re-introduction plan: caloric intake should be increased gradually (200–300 kcal per week) to prevent rebound hyperphagia, which is documented in GLP-1 withdrawal literature. If used alongside anabolic steroids, standard PCT for those compounds remains independent of semaglutide cessation.

Frequently asked questions

Does a GLP-1 agonist like semaglutide actually make sense during a caloric surplus bulk?: Yes — at a low titration dose, semaglutide moderates hyperphagia without fully suppressing the caloric surplus needed for hypertrophy. Athletes use it to replace chaotic high-volume eating with structured, satiating meals, which tends to reduce excessive fat accumulation during offseason phases without eliminating the energy surplus. Semapic's 1 mg/3 ml concentration allows fine-grained dosing adjustments as the offseason progresses.
How do competitive bodybuilders incorporate semaglutide during a pre-contest cut?: During contest prep, semaglutide is used to sustain dietary adherence over a 12–20 week cut by reducing diet-break events driven by hunger. It does not directly oxidise fat; instead it supports consistent caloric deficits by maintaining satiety signalling. Athletes pair it with protein intakes above 2.2 g/kg body weight and progressive cardio, using the STEP-programme titration schedule as a reference for weekly dose increments.
What happens to training intensity and gym performance when using semaglutide?: Training output can temporarily decrease during the first 4–8 weeks of dose titration, largely due to reduced caloric intake rather than any direct neuromuscular effect. Once the body adapts to lower energy availability and dose is stabilised, most athletes report performance returning to baseline. Prioritising intra-workout carbohydrates and ensuring adequate total daily calories relative to training volume mitigates performance drop-off.
What makes the 1 mg/3 ml Semapic pen the lowest-concentration option in this product group, and why does that matter?: Semapic delivers 1 mg of semaglutide in a 3 ml prefilled pen, making it the smallest available dose unit in this GLP-1 product category. This entry-level concentration is ideal for first-time users titrating up from 0.25 mg weekly, as smaller dose increments reduce the risk of GI side effects including nausea and delayed gastric emptying. It is particularly useful for bodybuilders starting their first GLP-1-assisted offseason block.
How should the Semapic prefilled pen be stored, and how long does it remain stable after first use?: Unused Semapic pens must be refrigerated at 2–8 °C and kept away from direct light; once a pen has been activated for its first injection, it may be stored at room temperature (up to 30 °C) for a maximum of 56 days per manufacturer guidance aligned with semaglutide product monographs. The pen should never be frozen. After 56 days of use, the remaining cartridge volume should be discarded regardless of residual solution. (2) angle_used

Manufacturer

Pharmacona is a pharmaceutical manufacturer whose product portfolio is built around high-specificity peptide-based compounds, with Semapic representing the company's entry into the GLP-1 receptor agonist category. The Semapic line is Pharmacona's prefilled-pen format designed to meet Pharma Grade quality standards, including GMP-certified production environments, HPLC-confirmed active ingredient purity, and LAL endotoxin batch release testing — a release protocol that distinguishes the Semapic range from compounded alternatives commonly encountered in performance markets. Pharmacona's peptide portfolio is developed with athlete-specific dosing formats in mind, prioritising convenience (prefilled dial-dose pens), traceability (per-batch certificates of analysis), and precise concentration control across its product lines.

Product details

Brand	Pharmacona
Active ingredient	semaglutide
Also known as	Semaglutid, Ozempic, Wegovy, Semapic, Pharmacona Semaglutid
Strength	1 mg
Form	Vial
Pack size	1 piece
Item number	WEIGHT-SEMA-PHA-004

Reviews

5/5

2 reviews

Rating: 5 out of 5 starsonyxVerified purchaseAug 3, 2026
Best sema I've used
On my second vial now. Running 0.5mg weekly, titrated up from 0.25mg over first three weeks. Down 12lbs in 7 weeks, waist went from 36 to 34 inches. No harsh sides, mild nausea week one only. Shipping was fast and box looked like nothing special from outside.
Rating: 5 out of 5 starsgymrat_30Verified purchaseJun 22, 2026
appetite completely gone
Honestly didn't believe it would work this well. Week two and I was eating maybe 1600 cals without even trying, lost 6lbs in the first three weeks alone. Pinning SubQ in the belly, zero PIP. Reordering next week.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

Ozempic 1mg/3ml 1 Pen by Novo Nordisk

Ozempic (semaglutide 1 mg/3 ml) is a prefilled subcutaneous pen that functions as a selective GLP-1 receptor agonist, engaging the endogenous incretin signalling axis to regulate postprandial glucose excursions, attenuate gastric motility, and sustain appetite suppression across a full weekly dosing interval. A C18 fatty-acid side chain anchors semaglutide to circulating albumin, conferring a plasma half-life of approximately 165–168 hours and enabling true once-weekly receptor engagement with minimal peak-to-trough fluctuation. Every Ozempic pen is released only after HPLC content verification, LAL endotoxin screening, and batch-level GMP compliance review at Novo Nordisk's certified manufacturing facilities.

€180.00

Purity Tested

Semapic 2mg/3ml 1 Pen by Pharmacona

Semapic is a prefilled subcutaneous semaglutide pen (2 mg in 3 ml) engineered for once-weekly administration, differentiated by its role in structured GLP-1 protocols that demand active countermeasures — specifically high dietary protein, progressive resistance training, and selective anabolic support — to preserve lean mass during caloric restriction. Each pen delivers dial-dose precision, removing guesswork from weekly injections during a fat-loss phase. Batch-level verification by HPLC chromatography and LAL endotoxin testing is performed under GMP-certified conditions; every unit leaving the Pharmacona facility carries documented purity certification.

€195.00

GMP Standard

Semaglutide 10mg/10ml 1 Vial by Swiss Pharma

Swiss Pharma Semaglutide 10mg/10ml is a subcutaneous GLP-1 receptor agonist supplied as a lyophilised or liquid concentrate in a single 10ml vial, formulated specifically around structured time-limited protocols — defining both the optimal run length and the clinical thresholds that require early termination. At 10mg per 10ml, this vial offers the highest per-unit concentration available in this product group, giving practitioners precise titration headroom across multi-week fat-loss cycles. Every batch of this product is released only after passing independent reversed-phase HPLC content verification and LAL (Limulus Amebocyte Lysate) endotoxin screening under GMP Standard conditions.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00